View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
September 30, 2009

Gedeon Richter Adopts Phase Forward’s Clintrial

For clinical trial data management activities

By CBR Staff Writer

Hungary-based, Gedeon Richter in a multi-year agreement plans to adopt Phase Forward’s Clintrial product for its clinical trial data management activities.

Gyorgy Nemeth, medical director at Gedeon Richter, said: “After an intense review process, Phase Forward’s dedicated services organisation and proven Clintrial product made our decision a clear one. We know that we are collaborating with the premier technology provider for clinical trials – and we look forward to garnering the benefits inherent in greater drug trial efficiencies.”

Steve Powell, senior vice president at Phase Forward, said: “We’re proud to be working with Gedeon Richter, one of Central-Eastern Europe’s leading pharmaceutical companies and an organisation dedicated to the kind of drug development work that will lead to much-needed new and generic therapies. It’s gratifying to have a company of Gedeon Richter’s reputation choose Phase Forward after such an extensive, thorough review process.”

Content from our partners
Rethinking cloud: challenging assumptions, learning lessons
DTX Manchester welcomes leading tech talent from across the region and beyond
The hidden complexities of deploying AI in your business

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.